BEDFORD, Mass., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to nine newly hired non-executive employees. The awards were made as an inducement material to each recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq List

mAbxience and Sandoz have entered into a collaboration agreement combining mAbxience's development and manufacturing expertise with Sandoz's global commercial capabilities for a proposed emicizumab biosimilar candidate. Emicizumab biosimilar expands mAbxience's pipeline into haemophilia A and strengthens its presence in rare diseases. The agreement is consistent with mAbxience's strategy of broadening patient access to high-quality biologic medicines through selected partnerships in global mar

Xenon Pharmaceuticals has paused enrollment in phase 3 depression trials after seeing adverse events, including psychosis. The biotech continues to treat existing participants in X-Nova2 and X-Ceed, phase 3 trials that are testing azetukalner in major depressive disorder (MDD) and bipolar depression, respectively. However, the company has voluntarily stopped enrolling new patients in the studies in response to reports of mostly mild or moderate adverse events. “What we’re seeing in psychiatry, w

LONDON, Sept. 18, 2026 /PRNewswire/ -- Business Worldwide Magazine's 20 Most Innovative Healthcare Companies to Watch, 2026 recognises organisations advancing innovation across the global healthcare landscape. Among those earning recognition is MyPureSkin S.A , a Swiss nutricosmetics company pioneering a science-led approach to skin health, longevity, and healthy ageing. Founded by Edgar Brandt and Tatiana Brandt in Switzerland's renowned Health Valley, MyPureSkin was established on a simple but

Bristol Myers Squibb has axed the degrader-antibody conjugate (DAC) it bought from Orum Therapeutics for $100 million, walking away from the asset after seeing phase 1 data. Orum, which disclosed (PDF) the news in a financial filing, sold the DAC to BMS in 2023. The therapy, dubbed ORM-6151, delivers a GSPT1 degrader to cells expressing CD33. Degrading the housekeeping protein GSPT1 can lead to cell death. Because acute myeloid leukemia and myelodysplastic syndrome cells often express CD33, ORM-

Financing led by Maven Capital Partners, alongside Gresham House Ventures Funds to be used to expand Metrion’s Cambridge UK laboratories and to enhance scientific and commercial capabilities Dr David Milroy and Steve Carle appointed to the board CAMBRIDGE, England--(BUSINESS WIRE)-- Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, today announced that it has secured £3.5m in new equity financing, including £2.5m from lead investor Maven Capital Pa

Electra Therapeutics is the latest biotech to overshoot its own IPO expectations this year, with the inflammation-focused company bringing in $350 million from this morning’s Nasdaq listing. South San Francisco-based Electra had been betting on selling 21.7 million shares priced around $15 apiece. But the biotech revealed Thursday evening that it managed to sell 23.3 million shares. It means the IPO has brought in gross proceeds of $350 million—above the $296.6 million net proceeds that the comp

CMS is dramatically expanding its digital health payment experiment, adding coverage for heart failure, chronic obstructive pulmonary disease, substance use disorders and nicotine dependence just months after launching the program. The expansion of the Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) Model, announced in mid September, will begin in spring 2027 and brings the total number of covered conditions to 11. CMS estimates that three out of four Medicare beneficiaries no

Novartis is pulling the plug on its amyotrophic lateral sclerosis (ALS) programme for VHB937 (lifonebart) after the experimental monoclonal antibody came up short in a Phase II study, the company confirmed to FirstWord Wednesday. The miss deals a setback to the company's efforts to harness immune cells of the central nervous system against neurodegenerative disease.Microglia carry a surface protein called TREM2, which when activated, shifts the immune cells into a more protective mode. VHB937 is

Financing led by The Column Group with participation from Nextech Invest, RA Capital Management, Euclidean Capital and a strategic investment from Eli Lilly and Company CID-165, a first-in-class oral macrocyclic cyclin D1 RxL inhibitor, is expected to enter clinical development in Q1 2027 for patients with ER+ breast cancer CID-165 has demonstrated robust anti-tumor activity in cyclin D1-driven preclinical cancer models, including in combination with CDK4/6-dual inhibitors, CDK4-selective inhibi